ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.

Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”

ARCS has launched a comprehensive Core Competency Framework tailored for the Medtech and Pharmaceutical sectors. The framework is designed to ensure members possess the specialised knowledge and skills required to excel within the sector, aiming to set benchmark for professional excellence.

“Our Core Competency Framework is a milestone in our journey to elevate professional standards for those working within the sector,” said Dr Boyle,. “It provides a structured pathway for continuous professional development common to all sectorial occupations and ensures our members are equipped with the expertise needed to meet professional demands.”

Expanding upon the Core Competency Framework, ARCS has also established international partnerships with the Association of Clinical Research Professionals (ACRP), the Regulatory Affairs Professionals Society (RAPS), and the International Society of Pharmacovigilance (ISoP) to recognise their occupation specific competency frameworks and accreditation standards. These partnerships aim to facilitate the creation of professional training pathways aligned with globally recognised best practice for sectorial occupations.

“Our alliances with ACRP, RAPS, and ISoP are pivotal in offering our members access to globally recognised professional pathways and raising the standard of Australian professionals through globally recognised professional accreditation,” said Dr Boyle.

“These collaborations help raise the bar and advance the professional standing of Australian Medtech and Pharmaceutical professionals on a global playing field.”

In recognition of professional excellence, ARCS will now issue postnominals to professional members based on their expertise. The aim of this designation is to underscore a member’s commitment to the highest standards of practice and their specialised expertise.

“The initiatives we are announcing today mark a new era for ARCS,” Dr Boyle concluded. “By establishing a robust competency framework, recognising professional excellence through postnominals, fostering international collaborations, and honouring our distinguished Fellows, we are setting a new standard for professionalism within the Australian Medtech and Pharmaceutical sectors.”